Downstream purification can be a time and cost-intensive step in clinical batch production for monoclonal antibodies and their derivatives. Biotech and biopharma companies who transfer their early-stage assets to our Mammalian Biologics CDMO Services, benefit from our downstream purification platform as part of process optimization. Watch on-demand webinar to learn how.
A cash pay model for prescription drugs can help biopharmaceutical companies meet consumer expectations. However, the model isn't right for every product; out-of-pocket costs, and a capable pharmacy partner, are two key considerations.
ISCT’s H1 2024 report provides a global overview of CGT regulations, highlighting pipeline trends, regulatory updates, and advancements in non-genetically and genetically modified therapies.
The “e” in eConsent could stand for much more than 'electronic'. Duke’s new research shows why participants prefer an eConsent experience bolstered with videos, media, questions, and more.
Identifying manufacturing capacity that can adapt to a growing and changing biopharma landscape requires an emphasis on technical and operational expertise combined with agility and flexibility.
Are your current training methods costly and time-consuming? Explore the benefits of blended learning, which can be up to four times faster than traditional training methods.
Middlesex County, NJ, offers life sciences organizations a deep talent pool, an extensive R&D presence, and dedicated backing by local government investment.
This website uses cookies to ensure you get the best experience on our website. Learn more